Advances in the Management of Metastatic
Head and Neck Squamous Cell Carcinoma (HNSCC): A Closer Look at the
Integration of Immunotherapy
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the live session at the 2017 Fall
Forum. If you participated in the live session, you are not eligible
for continuing education credits from this archive.
This activity is valid from June 10, 2018 to
June 30, 2019
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
an educational grant from
Merck & Company
Head and neck squamous cell carcinoma (HNSCC) affects the mouth,
throat, and nasal cavity. The prognosis is fatal once the cancer
metastasizes, giving patients, on average, about 5 years to survive.
Symptoms may range from mouth ulcers, bleeding or pain the mouth,
chronic sinus congestion, sore throat, pain when swallowing, and
difficult breathing. Thankfully novel treatments in immunotherapies
have proven efficacious, providing an increased survival rate and
improved quality of life for patients.
Upon Completion of this
activity, participants will be able to:
Analyze data on new immunotherapies
for treatment of metastatic HNSCC after disease progression
Examine the role of anti–PD-1
immunotherapy in the management of metastatic HNSCC
Review immune-related adverse events
& potential management strategies associated with the use of
Identify metastatic HNSCC patients
who would potentially benefit from immunotherapies
||Ezra Cohen, MD
Professor of Medicine
UC San Diego Health - La Jolla
Moores Cancer Center
serves as a consultant to AstraZeneca, Bristol-Myers
Squibb, Eisai, Human Longevity, Inc., Merck & Co, and
Pfizer. His Presentation has been reviewed for any bias.
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
supported by an educational grant from
Merck & Company
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue